CXCR4 and pancreatic neoplasm: Morimoto et al. demonstrated that the treatment of sensitive and resistant human pancreatic cancer cell lines, MIA PaCa-2 and AsPC-1, with gemcitabine chemotherapy increased the expression of CXCR4 in resistant cell lines [102].